Please enter the email address you used to register, then we will send you a link to choose a new password
On Monday, major U.S. indices closed in positive territory. The Dow Jones Industrial Average rose 0.6% to finish at 40,896.53.
Alzamend Neuro stock rises after partnering with Massachusetts General Hospital for a Phase 2 trial of AL001 to treat PTSD. The...
ALZN: 248% | Alzamend Neuro Partners With Massachusetts General Hospital For First-of-Its-Kind Phase II Study Of AL001 For PTSD...
Harvard Associate Professor Dr. Ovidiu Andronesi To Lead Study Comparing AL001 To Marketed Lithium Carbonate In Human Brain
Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the studyHead-to-he...
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel...
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend" or the "Company"), a clinical-stage biopharmaceutical company fo...